Biotechnology Secondary Use Of Samples Law In Russia.
1. Introduction
Biotechnology secondary use of samples in Russia concerns the legal regulation of using previously collected human biological materials for purposes different from those for which they were originally obtained.
In biotechnology, biological samples may include:
Blood, plasma and serum samples.
Human tissues and biopsy specimens.
DNA and RNA samples.
Human cells and stem cells.
Reproductive biological materials.
Tumour and cancer specimens.
Biological fluids and other human-derived materials.
Secondary use occurs when a hospital, laboratory, university, biotechnology company or research institution uses an existing sample for a new scientific, diagnostic, pharmaceutical or commercial research purpose.
For example, a patient's blood may initially be collected to diagnose an infectious disease. Several years later, a biotechnology company may wish to use the stored sample for genetic research or drug development.
This creates important legal questions:
Does the original consent cover the new research?
Can a hospital transfer stored samples to another research institution?
Can anonymised samples be used without obtaining fresh consent?
Can biological samples be used for commercial biotechnology research?
What happens when genetic information is generated from previously collected samples?
Can samples or genetic data be transferred outside Russia?
Russia does not have one comprehensive federal statute governing every aspect of secondary use of human biological samples. Instead, several federal laws, regulatory instruments and national standards operate together.
The principal legislation includes:
Federal Law No. 323-FZ of 21 November 2011, concerning the protection of public health.
Federal Law No. 152-FZ of 27 July 2006, concerning personal data.
Federal Law No. 86-FZ of 5 July 1996, concerning genetic engineering.
Federal Law No. 61-FZ of 12 April 2010, concerning the circulation of medicines.
Federal Law No. 180-FZ of 23 June 2016, concerning biomedical cellular products.
A particularly important development is the introduction of Article 13.2 into Federal Law No. 86-FZ in February 2026, addressing the transfer of certain human genetic data.
CIS Legislation+2
2. Legal Framework Governing Secondary Use
A. Federal Law No. 323-FZ: Protection of Public Health
Federal Law No. 323-FZ is one of the most important legal instruments governing the use of human biological samples in Russia.
Its provisions protect patients' rights, medical confidentiality and informed consent.
Article 20 – Informed Voluntary Consent
Article 20 establishes the principle of informed voluntary consent for medical intervention.
In the context of biological sample collection, institutions should ensure that patients understand the nature and purpose of the relevant medical procedure.
For secondary research, the critical question is whether the original consent adequately covers the proposed subsequent use.
Consent to diagnostic testing should not automatically be interpreted as unrestricted permission for unrelated genetic research, commercial development or international distribution.
Article 13 – Medical Confidentiality
Article 13 protects information concerning:
A patient's medical consultation.
Health conditions and diagnoses.
Medical examination and treatment.
Other information obtained during medical care.
Disclosure of medical-confidential information for scientific research generally requires written consent, subject to statutory exceptions.
Consequently, transferring a patient's tissue sample together with identifiable clinical information may create medical-confidentiality obligations even where the physical sample itself is not directly identifiable.
CIS Legislation+1
B. Federal Law No. 152-FZ: Personal Data Protection
Federal Law No. 152-FZ is particularly important when biological samples are associated with personal or genetic information.
Under Article 5, personal-data processing must comply with principles including:
Lawfulness and fairness.
Specified and legitimate purposes.
Purpose limitation.
Data minimisation.
Appropriate retention periods.
Article 6 establishes the legal grounds for processing personal data.
Article 10 provides additional protection for special categories of personal data, including health-related information.
Article 11 addresses biometric personal data.
Application to secondary sample use
Suppose a research institution has stored blood samples collected during a hospital study.
If the institution later analyses those samples to identify genetic predispositions to particular diseases, it must separately consider:
The legal basis for processing associated personal data.
Whether the original research purpose covers the new project.
Whether the data are identifiable or pseudonymised.
Whether the new processing requires additional consent.
Whether information will be disclosed to third parties.
Anonymisation can reduce privacy risks, but merely replacing a patient's name with a numerical code does not necessarily make the sample anonymous.
Genetic information can sometimes permit identification through comparison with other datasets.
static-0.minzdrav.gov.ru+1
C. Federal Law No. 86-FZ: Genetic Engineering Regulation
Federal Law No. 86-FZ is significant when secondary research involves human genetic information obtained through population-genetic or immunological studies.
A major recent development is Federal Law No. 43-FZ of 20 February 2026, which introduced Article 13.2 into Law No. 86-FZ.
Article 13.2 establishes restrictions on transferring human genetic data obtained through population-genetic and/or immunological research to specified foreign persons and organisations, including foreign recipients located in Russia and recipients outside Russia.
The statutory definition of transfer is broad. It encompasses:
Collection.
Storage.
Provision of access.
Transmission.
Dissemination.
Making the genetic information available through information networks.
Exceptional transfers are possible under the statutory procedure.
Legal significance: A research institution cannot assume that anonymisation or a material-transfer agreement automatically authorises international access to genetic data covered by Article 13.2.
Importantly, this provision concerns the specified category of genetic data. It should not be incorrectly interpreted as a universal prohibition on exporting every human biological sample.
Consultant Plus+1
D. Federal Law No. 61-FZ: Circulation of Medicines
Federal Law No. 61-FZ regulates pharmaceutical research, clinical trials and the development of medicinal products.
Its clinical-trial framework permits biological sampling, including blood, tissues, secretions and biopsy materials, for research inside or outside Russia.
Article 43 is particularly relevant to biological sampling during clinical trials.
However, permission to collect samples during an authorised clinical trial does not automatically authorise their unrestricted use in unrelated future research.
The proposed secondary use must be assessed against the applicable clinical-trial documentation, informed-consent requirements, confidentiality rules and international-transfer restrictions.
WIPO+1
E. Federal Law No. 180-FZ: Biomedical Cellular Products
Federal Law No. 180-FZ regulates the development, research, clinical testing, production, storage and use of biomedical cellular products.
It also regulates the donation of biological materials for the production of such products.
An important limitation is that Article 1 excludes certain activities from its scope, including the handling of human cells and tissues for scientific and educational purposes.
Therefore, ordinary scientific secondary use of stored human tissue should not automatically be treated as an activity regulated by the biomedical cellular-product regime.
The correct legal framework depends on the intended use of the material.
For example:
Scientific examination of stored tissue may fall outside Law No. 180-FZ.
Production of regulated biomedical cellular products may fall within it.
Transplantation and reproductive applications are governed by their respective legal regimes.
CIS Legislation+1
3. Biobanking and Secondary Use of Biological Samples
Biobanks are important institutions for secondary biotechnology research.
They collect, process, classify, preserve and distribute biological materials and associated information.
Russia has developed national standards addressing biobanking.
One important instrument is GOST R 71251-2024 – Biotechnology. Biobanking. Terms and Definitions.
This standard addresses matters including:
Primary and secondary biological samples.
Sample collection and processing.
Long-term storage.
Donor identification and de-identification.
Informed consent.
Withdrawal from research.
Confidentiality.
Material-transfer agreements.
Its definition of informed consent for biobanking recognises the importance of informing donors about the duration, purposes and persons or organisations that will use the material.
The standard also recognises the concept of withdrawal from research.
Legal importance: GOST R 71251-2024 provides useful technical and organisational guidance, but it should not be confused with a comprehensive federal statute creating independent permission for every secondary use.
Its legal force must be assessed under the Russian standardisation framework and any applicable contractual or regulatory requirements.
ГАРАНТ+2
4. Informed Consent for Secondary Use
Informed consent is one of the most important legal safeguards in Russian biotechnology research.
A researcher should distinguish between three situations.
Situation 1: Original consent expressly permits future research
A donor may have agreed that their sample can be retained and used for specified future biomedical research.
If the new research falls within the authorised scope and all other legal requirements are satisfied, additional consent may not be necessary.
Situation 2: Original consent is limited to a particular study
A patient may have authorised the use of a blood sample exclusively for cancer diagnosis.
Using that sample years later for unrelated reproductive genetics or commercial pharmaceutical research raises a different consent question.
The institution should not assume that the original diagnostic consent covers the new activity.
Situation 3: Original consent does not address future use
Where the original consent is silent or unclear, the research institution should examine whether another statutory legal basis exists.
Where necessary, it should obtain fresh informed consent before undertaking the new research.
Essential elements of a secondary-use consent
A well-designed consent document should explain:
The type of biological material being retained.
The original collection purpose.
The proposed future research purposes.
The duration of storage.
Whether genetic sequencing will take place.
Whether samples will be shared with other institutions.
Whether commercial research is contemplated.
Whether international transfer is anticipated.
The arrangements for confidentiality and anonymisation.
The procedure for withdrawal and the practical limits of withdrawal.
A broad consent document should not be treated as permission to disregard mandatory privacy, medical confidentiality or genetic-data restrictions.
5. Commercial Use of Previously Collected Samples
Commercial secondary use is a particularly complicated area.
For example, a pharmaceutical company may receive stored human tissue to develop a new cancer medicine.
The legal analysis involves several distinct questions:
Was the original collection lawful?
Does the donor's consent cover the proposed commercial research?
Does the transfer comply with medical confidentiality and personal-data rules?
Is the recipient authorised to conduct the relevant research?
Are export-control restrictions applicable?
Does the material-transfer agreement limit subsequent distribution?
Russian legal scholarship has identified unresolved questions concerning the legal status of biobanks, the ownership or legal regime of stored biological materials and the contractual relationships between donors, biobanks and research organisations.
A material-transfer agreement is therefore important, but it cannot replace the donor's legally required consent or override mandatory statutory restrictions.
law-journal.hse.ru+2
6. Cross-Border Secondary Use of Biological Samples
International biotechnology research creates additional compliance obligations.
For example, a Russian laboratory may send previously collected tumour samples to a German pharmaceutical company for genomic analysis.
The parties must distinguish between:
Export of the physical biological sample.
Transfer of associated personal data.
Transfer of medical-confidential information.
Transfer of genetic data.
Subsequent access by foreign researchers.
These are legally distinct activities.
The physical sample may be subject to customs and export-control restrictions even where the associated data are anonymised.
The relevant framework includes Federal Law No. 183-FZ of 18 July 1999 on Export Control and the applicable Eurasian Economic Union rules.
Article 13.2 of Law No. 86-FZ adds a separate restriction for the specified population-genetic and immunological research data.
A research institution should therefore conduct an export-control and data-transfer assessment before dispatching biological materials internationally.
7. Important Case Laws and Judicial Decisions
There is an important limitation in Russian jurisprudence: publicly identifiable judgments specifically deciding whether a previously collected human sample can be reused for an unrelated research purpose remain limited.
Nevertheless, Russian courts and the European Court of Human Rights have developed relevant principles concerning medical confidentiality, biological-material exports and research-related transfers.
Case 1. Avilkina and Others v. Russia (2013)
European Court of Human Rights · Application No. 1585/09 · 6 June 2013
Facts:
The applicants challenged the disclosure of confidential medical information to prosecutorial authorities following their refusal of blood transfusions.
The medical information was disclosed without their consent.
Legal issue:
Whether the disclosure of confidential medical information without adequate justification violated the right to privacy under Article 8 of the European Convention on Human Rights.
Decision and legal principles:
The European Court examined the necessity and proportionality of disclosing confidential medical information.
It emphasised the importance of protecting sensitive medical information and preventing unjustified interference with private life.
Relevance to secondary sample use:
Although the case did not concern biological samples directly, it provides an important principle for biotechnology institutions.
Where stored biological samples are accompanied by identifiable medical records, researchers must protect the confidentiality of the associated information.
A hospital should not assume that possession of a sample gives it unrestricted authority to disclose the patient's medical history to another research institution.
HUDOC+1
Case 2. StarExpert LLC v. North-West Electronic Customs (2024)
Arbitration Court of the North-Western District · Case No. A56-36287/2023 · 7 March 2024
Facts:
StarExpert LLC exported human biological samples to a foreign recipient for laboratory research.
The company relied on a document issued by Roszdravnadzor concerning the export of biological materials for diagnostic purposes.
The customs authorities subsequently challenged the export under Russian export-control rules.
Legal issue:
Whether a healthcare regulatory document was sufficient to establish compliance with the separate export-control requirements applicable to human biological materials.
Decision:
The court upheld the refusal to grant the company's challenge.
It considered the regulatory classification of the samples and the applicable export-control requirements.
Legal principle:
Permission or documentation from a healthcare regulator does not automatically establish compliance with all export-control obligations.
Relevance to secondary use:
This decision is important when biological samples collected in Russia are sent to foreign institutions for secondary research.
A laboratory must establish the actual intended purpose and the applicable export-control classification rather than relying exclusively on a diagnostic or healthcare-related authorisation.
sudact.ru+1
Case 3. National BioService LLC v. North-West Electronic Customs (2024)
Arbitration Court of the North-Western District · Case No. A56-56945/2023 · 30 January 2024
Facts:
National BioService LLC exported human biological material, including a tissue sample from a patient with lung cancer, to a foreign research recipient.
The sample was intended for laboratory research.
Customs authorities treated the shipment as subject to export-control restrictions.
Legal issue:
Whether exporting human biological samples for foreign research without satisfying the relevant export-control requirements constituted an administrative offence.
Decision:
The court examined the applicable restrictions under Article 16.3 of the Russian Code of Administrative Offences.
The judgment maintained the finding of an export-control violation, while addressing the administrative penalty imposed on the company.
Legal principle:
Biological materials intended for research may fall within controlled export categories. Their non-commercial or research-related purpose does not automatically exempt them from export-control requirements.
Relevance to secondary use:
This decision is particularly relevant to biotechnology companies operating international research programmes.
A sample collected for legitimate medical purposes may subsequently be exported for research, but its original lawful collection does not eliminate the need to comply with export restrictions governing its later movement.
sudact.ru+1
Case 4. Y.Y. v. Russia (2016)
European Court of Human Rights · Application No. 40378/06 · 13 December 2016
Facts:
The case concerned reproductive treatment and the restrictions imposed on an individual's access to assisted reproduction.
Legal issue:
The Court considered reproductive autonomy and the protection of private life under Article 8 of the European Convention on Human Rights.
Relevance to secondary sample use:
This is not a biobank or secondary-sample judgment. Its relevance is indirect.
It illustrates the importance of personal autonomy and private life in reproductive medicine. These principles are relevant when stored reproductive biological materials are considered for subsequent research or other uses.
The case should not be cited as establishing a specific legal right to control every subsequent use of stored reproductive samples.
globalhealthrights.org
Case-law position
The decisions above establish useful principles, but they do not collectively create a comprehensive judicial doctrine on secondary use of samples.
In particular, Russian case law has not clearly settled all questions concerning:
Ownership of stored biological samples.
The precise limits of broad consent.
Commercial secondary use of anonymised tissue.
Withdrawal after samples have been incorporated into research.
Re-identification of previously anonymised genetic material.
Destruction of samples following withdrawal.
These issues must therefore be analysed primarily through legislation, consent documentation, contractual arrangements and applicable research standards.
8. Legal Liability for Unauthorised Secondary Use
A research organisation may face different forms of liability depending on the nature of the violation.
| Violation | Potential legal consequences |
|---|---|
| Unlawful processing of personal data | Administrative liability under data-protection legislation |
| Unauthorised disclosure of medical secrets | Legal liability under health-protection and other applicable laws |
| Unlawful medical intervention | Civil, administrative or other applicable liability |
| Export-control violations | Administrative or criminal liability, depending on the circumstances |
| Breach of research or transfer agreements | Contractual liability |
| Misuse causing injury | Civil compensation and potentially other liability |
Relevant legislation includes:
Article 13 of Federal Law No. 323-FZ.
Federal Law No. 152-FZ.
Article 137 of the Russian Criminal Code concerning unlawful collection or dissemination of information about private life, where its elements are established.
Article 13.11 of the Code of Administrative Offences concerning violations of personal-data legislation.
Article 16.3 of the Code of Administrative Offences concerning violations of import and export restrictions.
The precise offence and penalty depend on the conduct, applicable statutory provisions and circumstances.
9. Compliance Requirements for Russian Biotechnology Institutions
Hospitals, universities, laboratories and biotechnology companies should establish a documented secondary-use compliance system.
A practical compliance framework includes the following steps:
Original sample collection
Record the original collection purpose, donor consent, sample type and collection date.
Consent verification
Determine whether the original consent covers future research, genetic analysis, commercial development and external sharing.
Research-purpose assessment
Compare the original purpose with the proposed secondary research and identify whether additional consent or another legal basis is necessary.
Privacy protection
Apply pseudonymisation or anonymisation where appropriate and protect associated clinical and genetic information.
Ethical and regulatory review
Assess whether the project requires research ethics review, regulatory approval or additional authorisation.
Material-transfer agreement
Document permitted uses, storage periods, confidentiality, onward transfers, security measures and destruction or return requirements.
International transfer assessment
Examine customs requirements, export controls, personal-data rules and the restrictions under Article 13.2 of Law No. 86-FZ.
Monitoring and accountability
Maintain sample inventories, access records, consent documentation, transfer records and procedures for responding to withdrawal requests.
10. Major Legal Challenges
Several unresolved issues create difficulties for Russian biotechnology regulation.
1. Broad consent versus specific consent
Researchers need flexibility for future discoveries, but donors must understand the purposes and risks of future research.
2. Ownership of biological materials
The legal relationship between donors, medical institutions and biobanks remains insufficiently clarified in some situations.
3. Anonymisation and genetic identification
Removing names and identification numbers does not always prevent the identification of individuals through genetic comparison.
4. Commercial exploitation
The law must balance biotechnology innovation, contractual freedom, donor autonomy and privacy protection.
5. International research cooperation
Foreign research partnerships must comply with sample-export requirements and the increasingly important restrictions on genetic-data transfers.
6. Withdrawal of consent
The withdrawal of a donor should be addressed through clear procedures. However, withdrawal cannot necessarily reverse completed analyses, published findings or irreversible incorporation of material into research products.
11. Conclusion
Biotechnology secondary use of samples in Russia is governed by a combination of healthcare legislation, personal-data protection, genetic-engineering regulation, pharmaceutical research rules and biobanking standards.
Federal Law No. 323-FZ protects patient autonomy and medical confidentiality, while Federal Law No. 152-FZ establishes safeguards for personal information. Federal Law No. 86-FZ has acquired additional significance through the introduction of Article 13.2 in 2026, which restricts specified transfers of human genetic data obtained through population-genetic and immunological research.
The 2024 arbitration decisions involving StarExpert LLC and National BioService LLC demonstrate that exporting biological samples for research requires careful attention to export-control legislation.
The central legal principle is that lawful collection of a biological sample does not automatically establish unrestricted authority to reuse, disclose, commercialise or export it.
Russian biotechnology institutions should therefore ensure that secondary use is supported by an appropriate legal basis, valid consent where required, confidentiality safeguards, regulatory compliance and documented transfer arrangements.
12. Important Legislation and Research References
| Legal instrument | Relevance |
|---|---|
| Federal Law No. 323-FZ (2011) | Healthcare, consent and medical confidentiality |
| Federal Law No. 152-FZ (2006) | Personal-data protection |
| Federal Law No. 86-FZ (1996) | Genetic engineering and genetic-data transfers |
| Federal Law No. 43-FZ (2026) | Introduced Article 13.2 |
| Federal Law No. 61-FZ (2010) | Pharmaceutical research and clinical trials |
| Federal Law No. 180-FZ (2016) | Biomedical cellular products |
| Federal Law No. 183-FZ (1999) | Export control |
| GOST R 71251-2024 | Biobanking terminology and practices |
Useful primary and academic sources:
Federal Law No. 323-FZ – Public Health Protection.
Federal Law No. 86-FZ – Article 13.2.
GOST R 71251-2024 – Biobanking.
Legal Status of a Biobank – Russian legal scholarship.
StarExpert LLC – Case A56-36287/2023.
National BioService – Case A56-56945/2023.
Avilkina and Others v. Russia (2013).
Legal research note: This explanation reflects the legislation and materials identified as of 18 November 2026. The Strasbourg judgments concern historical events and should be considered in light of Russia's cessation of participation in the European Convention on Human Rights on 16 September 2022. The case references above should not be interpreted as direct judicial rulings on every aspect of secondary sample use.
I can also prepare the next related research topic: Biotechnology Biobank Ownership, Consent and Secondary Research Liability Law in Russia – Detailed Explanation With Case Laws.

comments